HSBC Issues Pessimistic Forecast for Repligen (NASDAQ:RGEN) Stock Price

Repligen (NASDAQ:RGEN) had its target price dropped by equities researchers at HSBC from $170.00 to $150.00 in a report released on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the biotechnology company’s stock. HSBC’s target price suggests a potential upside of 23.07% from the company’s previous close.

A number of other brokerages have also issued reports on RGEN. Weiss Ratings raised Repligen from a “sell (d)” rating to a “sell (d+)” rating in a research report on Thursday, May 7th. Wells Fargo & Company cut their price objective on Repligen from $190.00 to $180.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 25th. HC Wainwright raised their price objective on shares of Repligen from $180.00 to $208.00 and gave the stock a “buy” rating in a research note on Monday, March 23rd. Royal Bank Of Canada started coverage on shares of Repligen in a research note on Thursday, May 14th. They set an “outperform” rating and a $160.00 price objective for the company. Finally, Wall Street Zen lowered shares of Repligen from a “buy” rating to a “hold” rating in a research report on Saturday, February 28th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Repligen currently has a consensus rating of “Moderate Buy” and a consensus target price of $164.64.

Repligen Stock Up 0.6%

NASDAQ RGEN traded up $0.76 during midday trading on Wednesday, hitting $121.89. 195,186 shares of the company traded hands, compared to its average volume of 953,747. The company has a debt-to-equity ratio of 0.26, a current ratio of 9.20 and a quick ratio of 7.78. The company has a market cap of $6.88 billion, a PE ratio of 135.27, a price-to-earnings-growth ratio of 2.37 and a beta of 1.09. The company’s 50-day simple moving average is $118.05 and its 200-day simple moving average is $139.53. Repligen has a 52 week low of $100.99 and a 52 week high of $175.77.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported $0.48 EPS for the quarter, beating analysts’ consensus estimates of $0.38 by $0.10. The company had revenue of $194.26 million during the quarter, compared to analysts’ expectations of $192.05 million. Repligen had a return on equity of 4.88% and a net margin of 6.73%.The firm’s revenue was up 14.8% compared to the same quarter last year. During the same period last year, the business posted $0.39 earnings per share. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. As a group, equities research analysts forecast that Repligen will post 1.99 earnings per share for the current year.

Institutional Trading of Repligen

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. AQR Capital Management LLC purchased a new stake in shares of Repligen in the 1st quarter valued at approximately $262,000. Jones Financial Companies Lllp lifted its position in shares of Repligen by 3,850.6% in the 1st quarter. Jones Financial Companies Lllp now owns 6,400 shares of the biotechnology company’s stock valued at $814,000 after acquiring an additional 6,238 shares in the last quarter. Goldman Sachs Group Inc. lifted its position in shares of Repligen by 16.8% in the 1st quarter. Goldman Sachs Group Inc. now owns 141,994 shares of the biotechnology company’s stock valued at $18,067,000 after acquiring an additional 20,375 shares in the last quarter. Bank of Nova Scotia lifted its position in shares of Repligen by 88.0% in the 2nd quarter. Bank of Nova Scotia now owns 31,747 shares of the biotechnology company’s stock valued at $3,951,000 after acquiring an additional 14,860 shares in the last quarter. Finally, Daiwa Securities Group Inc. lifted its position in shares of Repligen by 29.7% in the 2nd quarter. Daiwa Securities Group Inc. now owns 31,194 shares of the biotechnology company’s stock valued at $3,880,000 after acquiring an additional 7,148 shares in the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.